InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,022.59
(
0.20%
)

Replies to post #209204 on Biotech Values

Replies to #209204 on Biotech Values

DewDiligence

02/17/17 6:43 PM

#209206 RE: jq1234 #209204

Bad timing on the MNTA news-flow post, LOL. I'll update it for the new info.

DewDiligence

02/17/17 6:58 PM

#209207 RE: jq1234 #209204

MNTA 2017-2018 news flow (updated for delay to 40mg-Glatopa approval and other matters):

#msg-128817210

DewDiligence

02/24/17 7:09 PM

#209404 RE: jq1234 #209204

Fortunately, MNTA does not have to worry about liquidity—the 12/31/16 pro forma cash balance was $485.6M:

#msg-128997593

DewDiligence

02/13/18 8:30 AM

#217250 RE: jq1234 #209204

FDA approves NVS/MNTA’s 40mg Glatopa (generic Copaxone):

https://finance.yahoo.com/news/momenta-pharmaceuticals-announces-fda-approval-061500287.html

This approval was held up for one year by the manufacturing issue at PFE’s contract fill/finish plant in McPherson, KS (#msg-128816545).

Unfortunately for MNTA, MYL received FDA approval for its own (20mg and 40mg) generic Copaxone last fall, triggering considerable price erosion in the US Copaxone market. It’s now unlikely that anybody will make much money here.